Home / Business and Economy / Novo CEO Takes Helm at Lundbeck After Surprise Exit
Novo CEO Takes Helm at Lundbeck After Surprise Exit
19 Oct
Summary
- Lars Fruergaard Jorgensen is the new chair of H. Lundbeck A/S.
- He previously led Novo Nordisk A/S for eight years.
- His exit from Novo Nordisk occurred in 2025.
Lars Fruergaard Jorgensen has been appointed as the new chair of H. Lundbeck A/S. This marks his first prominent corporate leadership role since his departure from Novo Nordisk A/S.
Jorgensen led Novo Nordisk for eight impactful years before his unexpected exit from the obesity-drug maker in 2025. His new position at H. Lundbeck A/S signifies a new chapter in his distinguished career within the pharmaceutical industry.
The transition of such a high-profile executive highlights significant movement within the sector. H. Lundbeck A/S anticipates benefiting from Jorgensen's extensive experience.
This leadership change comes after Jorgensen's notable period at Novo Nordisk. His strategic direction there concluded with his departure in 2025, paving the way for this new endeavor.
